REAL-WORLD EVIDENCE IN RARE DISEASES IN FRANCE: TREATMENT PATTERNS, HEALTHCARE RESOURCE USE, AND RELATED COSTS IN VON WILLEBRAND DISEASE (FORVWARD STUDY)

被引：0
|
作者：
Trossaert, M. [1 ]
Andreani, Biron C. [1 ]
Micallef, Marant C. [2 ]
Nerich, V [3 ]
Lefevre, C. [4 ]
Nee, M. [5 ]
Walter, M. [2 ]
Belhassen, M. [5 ]
Favre-Besse, F. [6 ]
Chatelanaz, C. [6 ]
de Pouvourville, G. [7 ]
Beoletto, J. [6 ]
Polack, B. [8 ]
机构：
[1] CHU Nantes, Nantes, France
[2] PELyon, Lyon 69, France
[3] Univ Hosp Besancon, Besancon, France
[4] Takeda France, Courbevoie 93, France
[5] PELyon, Lyon, France
[6] Takeda France, Courbevoie, France
[7] ESSEC Business Sch, Cergy Pontoise, France
[8] CNRS, Grenoble, France
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PT41
引用
收藏
页码：S540 / S540
页数：1
相关论文
共 50 条
  • [31] Real-world insights into the management of hemophilia A in Italy: treatment patterns and healthcare resource utilization
    Perrone, Valentina
    Leogrande, Melania
    Cappuccilli, Maria
    Degli Esposti, Luca
    BLOOD RESEARCH, 2024, 59 (01)
  • [32] REAL-WORLD EVIDENCE ON HEALTHCARE RESOURCE USE AND ASSOCIATED COST WITH MULTIPLE MYELOMA IN THE NETHERLANDS
    Blommestein, H. M.
    Verelst, S. G.
    Zagorska, A.
    Stevanovic, J.
    Engstrom, A.
    Sonneveld, P.
    Huijgens, P. C.
    Lefevre, C.
    Uyl-De Groot, C. A.
    VALUE IN HEALTH, 2016, 19 (07) : A751 - A751
  • [33] Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors
    Huynh, Lynn
    Cai, Beilei
    Cheng, Mu
    Lax, Angie
    Lejeune, Dominique
    Duh, Mei S.
    Kim, Michelle K.
    PANCREAS, 2019, 48 (09) : 1126 - 1135
  • [34] Disparities in Real-World Treatment Patterns Among Patients with Von Willebrand Disease in a Large US Population-Based Dataset
    Weyand, Angela C.
    Sholzberg, Michelle
    Lai, Jacob S.
    Kim, Benjamin
    Rosenthal, Adam
    Robertson, Scott M.
    Patou, Gary
    Sidonio Jr, Robert F.
    BLOOD, 2024, 144 : 3978 - 3979
  • [35] Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real-World Evidence Study
    Morgans, Alicia K.
    Mucha, Lisa
    Quicquaro, Christina
    Shih, Vanessa
    Xie, Bin
    Young, Christopher
    Yang, Hongbo
    Liu, Qing
    Greatsinger, Alexandra
    Lax, Angela
    INTERNATIONAL JOURNAL OF UROLOGY, 2025,
  • [36] Real-world resource use and costs of adjuvant treatment for stage III colon cancer
    van Gils, C. W. M.
    de Groot, S.
    Tan, S. S.
    Redekop, W. K.
    Koopman, M.
    Punt, C. J. A.
    Uyl-de Groot, C. A.
    EUROPEAN JOURNAL OF CANCER CARE, 2015, 24 (03) : 321 - 332
  • [37] REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE COSTS AMONG PATIENTS WITH ADHESIVE CAPSULITIS IN THE UNITED STATES
    Tse, J.
    Banerji, T.
    Wang, E. J.
    Near, A.
    Davis, J.
    Hurley, D.
    VALUE IN HEALTH, 2022, 25 (07) : S342 - S342
  • [38] A REAL-WORLD STUDY OF HEALTHCARE RESOURCE UTILIZATION AND COSTS FOR SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN TAIWAN
    Tang, C. H.
    Chang, Y. S.
    Ng, K. J.
    Chuang, P. Y.
    Furnback, W.
    Wang, B.
    Wei, A.
    Treuer, T.
    VALUE IN HEALTH, 2022, 25 (07) : S599 - S600
  • [39] Comparison of real-world treatment patterns, persistence, healthcare resource utilization (HRU) and costs between octreotide and Lanreotide for the treatment of neuroendocrine tumors (NET)
    Lynn Huynh
    Cai, Beilei
    Lejeune, Dominique
    Cheng, Mu
    Lax, Angie
    Duh, Mei S.
    Cheng, Wendy
    Kim, Michelle K.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 134 - 134
  • [40] Comparison of real-world treatment patterns, persistence, healthcare resource utilization (HRU) and costs between octreotide and lanreotide for the treatment of neuroendocrine tumors (NET).
    Huynh, Lynn
    Cai, Beilei
    Sharperson, Camara
    Lejeune, Dominique
    Duh, Mei Sheng
    Kim, Michelle Kang
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345